Defining comorbidity: implications for understanding health and health services
JM Valderas, B Starfield, B Sibbald… - The Annals of Family …, 2009 - Annals Family Med
… in which the diseases appear is of particular interest in the study of etiological association
(b). … Starfield B. Threads and yarns: weaving the tapestry of comorbidity. Ann Fam Med. …
(b). … Starfield B. Threads and yarns: weaving the tapestry of comorbidity. Ann Fam Med. …
Substitution of doctors by nurses in primary care
…, J Braspenning, R Grol, B Sibbald - Cochrane database …, 2005 - cochranelibrary.com
Background Demand for primary care services has increased in developed countries due to
population ageing, rising patient expectations, and reforms that shift care from hospitals to …
population ageing, rising patient expectations, and reforms that shift care from hospitals to …
Understanding controlled trials. Why are randomised controlled trials important?
B Sibbald, M Roland - BMJ: British Medical Journal, 1998 - ncbi.nlm.nih.gov
… 17 Pilkington B, Kremer J. A review of the epidemiological research on child sexual abuse
… and Development Centre, University of Manchester, Manchester M13 9PL Bonnie Sibbald, …
… and Development Centre, University of Manchester, Manchester M13 9PL Bonnie Sibbald, …
International Study of Asthma and Allergies in Childhood (ISAAC): rationale and methods
…, EA Mitchell, N Pearce, B Sibbald… - European respiratory …, 1995 - Eur Respiratory Soc
The aetiology of asthma and allergic disease remains poorly understood, despite considerable
research. The International Study of Asthma and Allergies in Childhood (ISAAC), was …
research. The International Study of Asthma and Allergies in Childhood (ISAAC), was …
Worldwide variations in the prevalence of symptoms of atopic eczema in the International Study of Asthma and Allergies in Childhood
…, S Montefort, N Pearce, J Shah, B Sibbald… - Journal of allergy and …, 1999 - Elsevier
Background: Little is known about the prevalence of atopic eczema outside Northern Europe.
Objectives: We sought to describe the magnitude and variation in the prevalence of atopic …
Objectives: We sought to describe the magnitude and variation in the prevalence of atopic …
[HTML][HTML] Reduction in neural-tube defects after folic acid fortification in Canada
…, SH Uh, RB Lowry, B Sibbald… - … England Journal of …, 2007 - Mass Medical Soc
Background In 1998, folic acid fortification of a large variety of cereal products became
mandatory in Canada, a country where the prevalence of neural-tube defects was historically …
mandatory in Canada, a country where the prevalence of neural-tube defects was historically …
Worldwide variations in prevalence of symptoms of allergic rhinoconjunctivitis in children: the International Study of Asthma and Allergies in Childhood (ISAAC)
D Strachan, B Sibbald, S Weiland… - Pediatric allergy and …, 1997 - Wiley Online Library
Background: As part of the International Study of Asthma and Allergies in Childhood (ISAAC),
prevalence surveys were conducted among representative samples of school children …
prevalence surveys were conducted among representative samples of school children …
[HTML][HTML] Effects of pay for performance on the quality of primary care in England
…, D Reeves, E Kontopantelis, B Sibbald… - … England Journal of …, 2009 - Mass Medical Soc
Background A pay-for-performance scheme based on meeting targets for the quality of
clinical care was introduced to family practice in England in 2004. Methods We conducted an …
clinical care was introduced to family practice in England in 2004. Methods We conducted an …
[PDF][PDF] Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages
B Visentin, JA Vekich, BJ Sibbald, AL Cavalli… - Cancer cell, 2006 - cell.com
S1P has been proposed to contribute to cancer progression by regulating tumor proliferation,
invasion, and angiogenesis. We developed a biospecific monoclonal antibody to S1P to …
invasion, and angiogenesis. We developed a biospecific monoclonal antibody to S1P to …
An implementation research agenda
…, S Michie, H Rogers, J Rycroft-Malone, B Sibbald - Implementation …, 2009 - Springer
In October 2006, the Chief Medical Officer (CMO) of England asked Professor Sir John Tooke
to chair a High Level Group on Clinical Effectiveness in response to the chapter 'Waste not, …
to chair a High Level Group on Clinical Effectiveness in response to the chapter 'Waste not, …